Literature DB >> 3838407

The new long-acting coronary artery dilator molsidomine and its metabolite SIN-1.

J Sobolski, P Vandermoten, E Stoupel, G Berkenboom, S Degre.   

Abstract

We studied the effects of intracoronary injections of SIN-1 (0.8 mg), the active metabolite of molsidomine, on coronary artery diameters and coronary stenoses. In nine patients with abnormal angiograms measurements were made 4 and 8 minutes after SIN-1 administration. There was a statistically significant increase in coronary luminal diameter in proximal, medial, and distal segments as well as at the level of the stenoses. At 4 minutes after administration distal segments showed a mean increase in diameter of 50%, compared to a mean increase of 26% in proximal segments. In six patients with normal angiograms SIN-1 abolished three of four coronary spasms induced by ergonovine maleate. A protective effect of SIN-1 against the vasoconstrictor effects of ergonovine was still present at 8 minutes after administration. Heart rate and blood pressure remained unchanged throughout the study. We conclude that the vasodilation induced by SIN-1 in normal and stenotic coronary arteries is probably an important contribution to the antianginal efficacy of molsidomine and suggests that molsidomine may be effective in the prophylaxis of variant angina.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838407     DOI: 10.1016/0002-8703(85)90686-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  3 in total

1.  Elimination of variable vasomotor tone in studies with repeated quantitative coronary angiography.

Authors:  S Jost; W Rafflenbeul; G H Reil; H J Trappe; D Gulba; H Hecker; U Gerhardt; I Knop
Journal:  Int J Card Imaging       Date:  1990

2.  Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease.

Authors:  M Kyriakidis; G Vyssoulis; P Sfikakis; C Kyriakidis; C Pitsavos; K Valsamis; V Nomikos; P Toutouzas
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Nonresponsiveness to antianginal therapy--a frequent problem?

Authors:  W Schulz
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.